Peri-Okonny PA, et al. - Researchers assessed the link between statin use and mortality after transcatheter aortic valve replacement (TAVR) among 3,956 high- or intermediate-surgical risk patients who had TAVR as a part of the PARTNER (Placement of Aortic Transcatheter Valves) II and Sapien 3 trials and registries. Using propensity score matching, they matched 626 patients on a statin with 626 patients not on a statin at discharge. They focused on 2-year all-cause, cardiovascular, and noncardiovascular mortality. Lower rates of cardiovascular and noncardiovascular mortality were reported in relation to statin use vs no statin use. This finding could be driven either by pleiotropic impacts or by residual confounding (even with propensity-matching methodology) given the early rise of the seeming protective influence of statins.